(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030194 A1

(51) International Patent Classification[7]: A61K 31/18, 31/426, 31/421, A61P 31/14

(21) International Application Number: PCT/EP2004/052388

(22) International Filing Date: 30 September 2004 (30.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03103629.6 30 September 2003 (30.09.2003) EP
60/507,535 1 October 2003 (01.10.2003) US

(71) Applicant *(for all designated States except US)*: TIBOTEC PHARMACEUTICALS LTD. [IE/IE]; Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SIMMEN, Kenneth Alan [GB/BE]; Boterbloemenlaan 35, B-3080 Tervuren (BE). VAN ACKER, Koenraad Lodewijk August [BE/BE]; Uilenberg 30, B-9140 Temse (BE). WIGERINCK, Piet Tom Bert Paul [BE/BE]; Kardinaal Cardijnstraat 29, B-2840 Terhagen (BE). SURLERAUX, Dominique Louis Nestor Ghislain [BE/BE]; rue de la scaillée, 13, B-1440 Braine-le-château (BE). DAMS, Géry Karel Julia [BE/BE]; Nieuwe Erven 11, B-3583 PAAL-BERINGEN (BE). QUIRYNEN, Ludo Maria Marcel [BE/BE]; Katelijnestraat 19F, B-2320 Hoogstraten (BE). HERTOGS, Kurt [BE/BE]; Albert I laan 185 bus 401, B-8260 Nieuwpoort (BE). PAUWELS, Rudi Wilfried Jan [BE/CH]; Chemin de Layaz 3, CH-1806 Saint-Légier La Chiésaz (CH).

(74) Agent: DAELEMANS, Frank; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: HCV INHIBITIING SULFONAMIDES



(I)



(57) Abstract: The present invention concerns sulfonamide derivatives having the general formula (I) and *N*-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q_1 is -S- or -O-; R_1 is hydrogen, C_{1-6}alkyl, hydroxy, amino, halogen, aminoC_{1-4}alkyl and mono-or di(C_{1-4} alkyl)amino; R_2 is hydrogen or C_{1-6} alkyl; R_3 is C_{1-6}alkyl, aryl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4} alkyl, or arylC_{1-4} alkyl; R_4 is hydrogen, C_{1-4} alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C C_{1-4}alkyl)aminocarbonyl, C_{3-7}cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from aryl, Het[1], Het[2], C_{3-7}cycloalkyl, C_{1-4}alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, aminosulfonyl, C_{1-4}alkylS(=O)$_t$, hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C_{1-4}alkyl, aryl, arylC_{1-4} alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, Het[1], Het[2] Het[1]C_{1-4}alkyl and Het[2]C_{1-4} alkyl; Q_2 is a radical of formulae (III, IV, V, VI, VII) for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present sulfonamides with other anti-HCV agents and/or anti-HIV agents.

WO 2005/030194 A1

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.